Technology explainer
Why Can a Drug Lower Cholesterol Without Yet Proving It Prevents Heart Attacks?
Trials may first measure biomarkers such as LDL cholesterol because they change quickly and predict risk. Preventing heart attacks or strokes requires larger, longer outcome trials that directly count clinical events.
A medicine can produce a large change in a laboratory measurement before researchers know whether it prevents illness or extends life. This distinction is common in cardiovascular drug development.
What is a surrogate endpoint?
A surrogate endpoint is a measurable sign, such as LDL cholesterol or blood pressure, used as a substitute for a later clinical outcome. It can make early trials faster and smaller.
Why is LDL cholesterol useful?
LDL is strongly linked to cardiovascular risk, and lowering it has reduced events across several proven treatment classes. That makes it an informative marker, but not every new mechanism is automatically guaranteed the same outcome.
What is a clinical outcome trial?
An outcome trial directly counts events such as heart attacks, strokes, hospitalization or death. These events occur less often than biomarker changes, so trials need more participants and longer follow-up.
Why can biomarker success fail to translate?
A treatment may cause unexpected side effects, affect other biological pathways or lower the marker without changing the disease process enough to improve outcomes.
When can regulators approve a drug before outcome data?
Approval may rely on a well-established surrogate when the evidence linking it to benefit is strong. Regulators can still require post-approval studies or additional outcome trials.
What should patients understand?
A strong biomarker result can be promising, but it is not identical to proof that the medicine prevents major events. Treatment decisions should consider the full evidence and individual risk.
First appeared in
The First Cholesterol Pill of Its Kind Can Cut LDL by Nearly 60%. Here Is What It Cannot Prove Yet
